Solid Organ Transplantation in SARS-CoV-2 Recovered Transplant Candidates: a Comprehensive Review of Recent Literature

Vivek Kute1 · Hari Shankar Meshram1 · Vidya A. Fleetwood2 · Sanshriti Chauhan1 · Krista L. Lentine2

Accepted: 14 February 2022 / Published online: 9 March 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract

Purpose of Review As the coronavirus disease 2019 (COVID-19) pandemic continues to surge, determining the safety and timing of proceeding with solid organ transplantation (SOT) in transplant candidates who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and who are otherwise transplant eligible is an important concern. We reviewed the current status of protocols and the outcomes of SOT in SARS-CoV-2 recovered patients.

Recent Findings We identified 44 published reports up through 7 September 2021, comprising 183 SOT [kidney = 115; lung = 27; liver = 36; heart = 3; simultaneous pancreas-kidney (SPK) = 1, small bowel = 1] transplants in SARS-CoV-2 recovered patients. The majority of these were living donor transplants. A positive SARS-CoV-2 antibody test, although not obligatory in most reports, was a useful tool to strengthen the decision to proceed with transplant. Two consecutive real-time polymerase chain test (RT-PCR) negative tests was one of the main prerequisites for transplant in many reports. However, some reports suggest that life-saving transplantation can proceed in select circumstances without waiting for a negative RT-PCR. In general, the standard immunosuppression regimen was not changed.

Summary In select cases, SOT in COVID-19 recovered patients appears successful in short-term follow-up. Emergency SOT can be performed with active SARS-CoV-2 infection in some cases. In general, continuing standard immunosuppression regimen may be reasonable, except in cases of inadvertent transplantation with active SARS-CoV-2. Available reports are predominantly in kidney transplant recipients, and more data for other organ transplants are needed.

Keywords COVID-19 recovery · Waitlist · Solid organ transplantation · Deceased donor · Living donor

Abbreviations

SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
SOT Solid organ transplantation
RT-PCR Real-time polymerase chain test
SPK Simultaneous pancreas-kidney transplant
IS Immunosuppression
COVID-19 Coronavirus disease-19
LDKT Living donor kidney transplantation
DDKT Deceased donor kidney transplantation
CT Cycle threshold
LDLT Living donor liver transplantation
DDLT Deceased donor liver transplantation
LT Lung transplantation

This article is part of the Topical Collection on COVID-19 and Transplantation

Vivek Kute, Hari Shankar Meshram, and Vidya A. Fleetwood are co-first authors. Krista L. Lentine is senior author.

Krista L. Lentine
krista.lentine@health.slu.edu

1 Department of Nephrology and Transplantation, Institute of Kidney Diseases and Research Center and Dr. H L Trivedi Institute of Transplantation Sciences (IKDRC-ITS), Ahmedabad, India

2 Center for Abdominal Transplantation, Saint Louis University School of Medicine, Saint Louis, MO, USA

Vivek Kute
drivekkute@rediffmail.com
Hari Shankar Meshram
hsnephrology@gmail.com
Vidya A. Fleetwood
vidyaratna.fleetwood@health.slu.edu
Sanshriti Chauhan
sanshrichauhan@gmail.com
Introduction

The coronavirus disease (COVID-19) pandemic has posed major challenges to the practice of transplantation worldwide [1••, 2]. The pandemic brought transplant activities to a standstill in different regions of the world, as per the regional COVID-19 toll and available resources [3]. The resumption of transplantation activities occurred in a staged and stepwise process with interruptions by COVID-19 waves [4]. However, there were efforts by many transplant teams to explore strategies for safely resuming transplantation activities within the initial phase of the pandemic.

Globally, as of 6 September 2021, there have been 220,563,227 confirmed cases of COVID-19 reported to the World Health Organization [5]. Such mammoth numbers are a matter of focus and concern for transplant teams, as it leads to a high numbers of COVID-19 recovered patients requiring organ transplant as well as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure prevalence among organ donors. We recently reviewed use of organs from SARS-CoV-2 infected donors after recovery from SARS-CoV-2 [6]. From the candidate perspective, a daunting question has arisen: how and when is it safe to proceed to transplant after COVID-19 infection? The answer to this is still not fully known and requires further review of the evidence.

An international registry study reported high rates of complications in general surgery patients with perioperative COVID-19 [7]. However, there are fewer such reports in the context of SOT. Notably, SOT recipients who contract COVID-19 in the early post-transplant period face an increased risk of adverse outcomes, suggesting that transplanting a patient with active or recently resolved COVID-19 may carry a higher rate of complications [8–10]. Hence, the decision to proceed with transplant after recent COVID-19 is a complex issue.

To advance understanding of this timely topic, we reviewed the available published evidence on SOT performed in patients who have recovered from COVID-19. We extracted information on eligibility criteria, testing protocols, and clinical outcome in this context.

Kidney Transplantation After Recovery From COVID-19

A total of 115 kidney transplants in patients who have recovered from COVID have been reported. The first case of living donor kidney transplantation (LDKT) where both donor and recipient recovered from COVID-19 illness was reported in Turkey in February 2021 [11]. Over follow-up of 45 days, the authors reported no complications in the donor-recipient pair. Similar case reports followed from different areas of the world [12]. But the most comprehensive insight into this topic was documented in an Indian study that reported 75 LDKT in recipients who had recovered from COVID-19 [13•]. The clinical protocol in this series mandated at least two consecutive negative RT-PCR reports, an asymptomatic period of 28 days, and a normal chest x-ray before transplant. The median waiting time from COVID-19 diagnosis until transplant was approximately 60 days in this report. A notable aspect of this cohort was that none of the patients had required mechanical ventilation during COVID-19 [14••]. However, the reported post-transplant follow-up was short, limiting assessment of long-term data. The same authors had previously reported 9 COVID-19 recovered donor-recipient pairs, with similar outcomes and follow-up [13•]. More detailed data for deceased donor kidney transplantation (DDKT) in COVID-19 recovered candidates came from a US report of 13 cases [15••], in which four patients had moderate to severe COVID-19, of which one required mechanical ventilation. Median waiting time post-COVID-19 was 71 days, and postoperative course for these patients at 3 months follow-up was reported to be uneventful (Table 1).

At some centers, transplant physicians have gradually shortened the waiting time from COVID-19 recovery to transplantation, and there are reports of transplants performed in candidates who were still COVID-19 positive. In an Italian report, DDKT was performed in a candidate with recovered COVID-19 at 29 days after the first negative PCR, a significantly shorter waiting time than the previously described median 60–71 days [16]. Some transplants have been performed in patients with active COVID-19; there are five reports of kidney transplants in candidates with positive RT-PCRs, including those with high cycle threshold (CT) values [17, 18] as well as those with neutralizing antibodies [19]. Additionally, successful simultaneous pancreas-kidney transplant (SPK) after COVID-19 recovery has been reported [20]. The majority of the published data about LDKT in COVID-19 recovered patients is from developing nations, while DDKT reports predominate in developed countries, likely attributable to the fact that deceased donation is still in its infancy in the developing world; however, safety profiles appear similar for both.

A European study recently studied antibody response in hemodialysis patients and found the immune response varied with the severity of infection. They also reported a low level of seroresponse and waning of antibody response in follow-up [21]. These data demonstrate that transplant candidates with previous COVID-19 are at theoretically more risk for re-infection or reactivation even after transplantation.
Table 1  Kidney transplantation in candidates with recovered or positive SARS-CoV-2 infection. COVID-19 severity was defined as asymptomatic in cases who had incidental detection, mild in those with only upper respiratory symptoms; moderate when requiring low flow oxygen, and severe in cases with higher oxygen requirement. * = Cases which were RT-PCR positive at the time of transplant surgery. Abbreviations: COVID-19, coronavirus disease; CKD, chronic kidney disease; CT, cycle threshold; DM, diabetes mellitus; DD, deceased donation; ESKD, end-stage kidney disease; F, female; HD, hemodialysis; IS: immunosuppression; LD, living donation; M, male; m, months; MMF, mycophenolate; nRT-PCR, real-time polymerase chain test through nasopharyngeal specimen; MN, membranous nephropathy; TIN, tubulointerstitial nephritis; TCR, T cell rejection.

| Authors                          | n | Type | Age/sex | Cause of ESKD | COVID-19 severity | Negative nRT-PCR prior to transplant | Waiting time after a negative RT-PCR test | IgG antibody test Pre-Transplant | Donor’s COVID-19 status | IS regimen | Outcome | Follow-up |
|---------------------------------|---|------|---------|---------------|------------------|---------------------------------------|------------------------------------------|--------------------------------------|----------------------------|-------------|----------|-----------|
| Singh N et al., Sept 2020 [20]  | 1 | DD   | 66/F    | DM            | Mild (home)      | 2 negatives (24 h apart)              | 3 mos                                   | Done (positive)                     | Negative                   | No change   | Uneventful | 7 wks     |
| Varotti et al., Oct 2020 [16]   | 1 | DD   | 28/F    | MN-CKD        | Mild             | 2 negative (48 h apart)               | 2 wks                                   | Done (positive)                     | Negative                   | No change   | E. coli infection | 60 d     |
| Waghmare I et al., Dec 2020 [12] | 1 | LD   | 46/M    | Not reported  | Severe           | ≥ 2                                    | 3 mos                                   | Not reported                         | Negative                   | No change   | Uneventful | 1 mos     |
| Singh N et al., Sept 2020 [20]  | 1 | DD   | 44/M    | DM            | Severe           | 2 negatives (24 h apart)              | 3 mos                                   | Done (positive)                     | Negative                   | No change   | Uneventful | 7 wks     |
| Singh N et al., Sept 2020 [20]  | 1 | LD   | 35/F    | CKD unknown   | Mild             | 3 negatives (24 h apart)              | 3 mos                                   | Done (positive)                     | Negative                   | No change   | Uneventful | 7 wks     |
| Viana L A et al., Jan 2021 [61] | 4 | DD   | 34/M    | Not reported  | Mild             | All 4 cases were RT-PCR positive      | -                                       | Negative in all                     | In 3 cases, MMF was halved | Two patients got TCR | 1 mos     |
| Kucuk et al., Feb 2021 [11]     | 1 | LD   | 31/M    | CKD unknown   | Mild             | 4 negatives (24 h apart)              | 30 d after recovery                      | Done (both negative)                | Positive with mild illness | No change   | None       | 45 d      |
| Murad et al., Feb 2021 [18]     | 1 | DD   | 64/F    | Alport syndrome | Mild           | Positive (high CT value)              | -                                       | Not reported                         | Negative                   | No change   | Uneventful | 4 mo      |
| Yoshinaga et al., March 2021 [67]| 1 | DD   | 49/M    | Not reported  | Moderate         | 3                                     | 3 mos                                   | Not done                            | Negative                   | No change   | Uneventful | 95 d      |
| Reyad Al et al., March 2021 [68]| 1 | DD   | 65/F    | CKD unknown   | Severe           | 3                                     | 46 d                                   | Positive                            | Negative                   | No change   | Uneventful | 2 mos     |
| Kute et al., April 2021 [13•]   | 9 | LD   | Median: 39 yr | HTN and DM   | Asymptomatic (n = 5) | ≥ 2 | 73 (34–92) d | Not mandatory | All donors were COVID-19 recovered | No change | Uneventful | 44 d      |
| Authors                        | $n$ | Type | Age/sex | Cause of ESKD | COVID-19 severity | Negative nRT-PCR prior to transplant | Waiting time after a negative RT-PCR | IgG antibody test Pre-Transplant | Donor’s COVID-19 status | IS regimen | Outcome | Follow-up |
|--------------------------------|-----|------|---------|----------------|-------------------|--------------------------------------|-------------------------------------|----------------------------------|------------------------------|-------------|----------|----------|
| Villanego F et al., May 2021 [69] | 1   | DD   | 70/M    | Chronic TIN    | Asymptomatic      | 3 consecutive negatives               | 3 mos. after first + ve             | Done (positive)                 | Negative                     | No change   | Uneventful | 2 mos    |
| Santausio AD et al., June 2021 [15••] | 13  | • DD:10 | Median: 2.8 yr | Sex: 84% M |                   |                                      | 1 Negative                          | Median of 71 d (56.6–135) | 10 out of 13; and all reports positive for antibodies | Negative                     | No change   | Uneventful: no difference vs controls | 3.6 mos |
| Puodziukaite et al., June 2021 [19] | 2   | DD   | • 38/F | • 36/M | HTN (38%) • DM (30%) | Mild (n = 9) • Moderate–severe (n = 3) • Mechanical ventilation (n = 1) | 1 Negative                          | 2.5 mos. after COVID-19 | Done (positive) | • RT-PCR + ve • Mild | No change   | Uneventful | 3 mos    |
| Hogan et al., July 2021* [17]    | 1   | DD   | 8/M     | Congenital nephrotic syndrome | Asymptomatic | Positive with high CT value | Active; RT-PCR + ve with high CT value | Done (positive) | Negative | No change | Uneventful | 44 d     |
| Tuschen et al., July 2021 [70]   | 1   | DD   | 65/F    | IgA nephritis | Moderate | 3 | 65 d | Positive | Negative | No change | Uneventful | 9 mos     |
| Kute et al., July 2021 [14••]    | 75  | LD   | Median: 47 (29–72) | Sex: M:23 F:52 | Not reported | Indication of early transplant: Difficult vascular access (n = 8) and severe left ventricular dysfunction (n = 12); Others: Financial constraint for continuing HD | ≥ 2 | Median: 60 d; Increased significantly from asymptomatic, mild, moderate, and severe disease (49, 57, 83, 94 d; $P = 0.019$), respectively | Not mandatory | COVID-19 recovered donors (n = 16) | No change | Uneventful | Median: 81 d (56–117) |
Lung and Heart Transplantation After Recovery From COVID-19

There are reports of successful extracorporeal membrane oxygenation (ECMO) use as salvage therapy in severe COVID-19 [22, 23]. But there are also considerable numbers of COVID-19 cases who fail ECMO and are potential candidates for lung transplantation (LT). The first case series of LT in a SARS-CoV-2 recovered patient was reported in a US study, where 3 patients suffering from irreversible lung injury benefited from LT [24]. There are also a few reports of successful LT in other nations [25–28]. In general, conducting a LT in a recipient after recovered SARS-CoV-2 infection is relatively difficult compared to other SOT. The logistics involved in a successful LT can be inferred from a report where a candidate with COVID-19 was transferred from Mexico to Korea for LT [29]. Some insight into the status of LT after recovery from SARS-CoV-2 comes from a recently published multi-institutional series of 12 cases [30••]. The authors proposed criteria for LT in COVID-19 patients with end-organ lung damage, suggesting that this procedure should be reserved for those aged < 65 years, and with approximately 4–6 weeks of irreversible lung injury. They also suggested two negative lower respiratory tract fluid RT-PCRs, and early weaning of sedation in the post-transplant period to promote early recovery. They also favored double lung transplantation, as the majority of their cohort had superimposed pulmonary hypertension. In follow-up, the outcomes of LT in patients recovered from COVID have been encouraging [31].

Another complex procedure is a heart transplant in a COVID-19 recovered patient. The first such case was performed in the USA [32]. In another report, a heart re-transplantation was performed in a patient in the recovery phase of COVID-19 with an RT-PCR positive report. The outcome was good but the patient remained SARS-CoV-2 positive until day 44 of follow-up [33]. There is also a report of emergency heart transplantation in a patient who developed fulminant myocarditis related to COVID-19 [34].

Liver Transplantation After Recovery From COVID-19

The first and largest cohort of living donor liver transplantation (LDLT) COVID-19 recovered patients was described in an Indian study [35••]. A US study described the first and largest series of deceased donor liver transplantation (DDLT) in COVID-19 recovered patients [36••]. There are also case reports from different parts of the world [37–39]. There has not been consensus on a specific waiting time before transplant, but 4 weeks seems justified. However, many reports describe proceeding to transplantation with no waiting time as transplant was judged to be a life-saving procedure. Liver transplantation has also been offered to COVID-19 recovered recipients with other complicating factors, such as HIV [40] and very young age (Table 2) [41].

Similar to kidney transplantation, the need for an interval from COVID-19 clearance has been challenged. In Italy, a DDLT was performed in as early as 9 days after being diagnosed with asymptomatic COVID-19 and just 2 days after a negative RT-PCR; the outcome was uneventful [42]. In another Italian report, a decision to perform an emergency DDLT was made, using a COVID-19 positive donor. The recipient was RT-PCR positive but had neutralizing antibodies [42]. In the USA, an emergency DDLT was performed in an RT-PCR positive critical COVID-19 patient. The decision to proceed was taken in view of his deteriorating liver illness and high CT values despite having no antibody response [43]. In the USA, an urgent DDLT was performed successfully in a patient who had COVID-19 illness for 2 months and was persistently RT-PCR positive at the time of transplant [44]. In general, there have been no obvious COVID-19 related complications in the follow-up of these cases. However, there are reports of portal venous thrombosis and hepatic artery thrombosis in two DDLT transplanted to COVID-19 recovered patients [45, 46]. Although the association of this complication with COVID-19 is not clearly delineated, it raises a word of caution. There are very few reports of reactivation or re-infection with COVID-19 following SOT in recovered patients. One such report demonstrated repeated positive viral loads till 1 month of successful DDLT. However, the patient remained asymptomatic throughout [47]. Post-COVID-19 cholangiopathy emerged as a new cause of chronic liver disease requiring transplantation in this pandemic [48, 49], but has not yet been reported as a complication of liver transplantation to COVID-19 positive recipients.

Deciding to Proceed to Transplantation: Weighing Risks vs Benefits

It is difficult to delineate any uniform guidelines for assessing eligibility for transplant in COVID-19 recovered patients. Various international bodies have come up with a consensus for surgeries in recovered patients. The American Society of Anesthesiologists and Anesthesia Patient Safety Foundation Joint Statement on elective surgery, published on 8 December 2020, recommended 4 weeks waiting time for asymptomatic or mild cases; 6 weeks for hospitalized
patients; 8–10 weeks for patients hospitalized with co-morbid conditions; and 12 weeks for severe cases [50]. The International Society of Heart and Lung Transplantation guidelines revised on 1 February 2021 recommended at least 1 negative RT-PCR with normal chest imaging along with no symptoms and waiting time of at least 14 days for asymptomatic, and 21 days for symptomatic COVID-19 cases [51]. If RT-PCR remains positive beyond 21 days of illness in a recovered candidate, the patient can still proceed for transplant. Recently, the Indian Society of Organ Transplant guidelines for SOT from recovered donors and recipients recommended at least 2 negative RT-PCR, with an asymptomatic period of 28 days and normal chest radiology before [52].

There are a few studies that have proceeded with one RT-PCR negative report, while some have more than 3 negative reports. From the available evidence, it is justified to document at least two negative RT-PCR reports, to eliminate the possibility of a false negative. The other salient criterion is that the patient must be asymptomatic after recovery. The optimal symptom-free duration before transplant is not known, but recovery for more than 1 month seems safe before an elective transplant. Nevertheless, there are reports of life-saving transplantation in extremely ill patients as well. As clinical practice and understanding have evolved with time in this pandemic, the threshold for proceeding to a transplant has become less strict. In the current era, there are no data to indicate that a particular waiting time is ideal for proceeding with SOT; this decision should be based solely on the urgency of transplant [53]. There is emerging evidence to support transplant from RT-PCR positive patients in some circumstances. The rationale behind proceeding for transplant here is the high lag time for a negative RT-PCR report in chronic conditions like chronic kidney disease. The studies which successfully transplanted such case were buttressed by a report of protective antibody level in many cases. There are multiple studies which show that a low cycle threshold of RT-PCR is associated with high viral loads; hence, candidates with persistently positive RT-PCRs but with high CT values, if asymptomatic, could be considered for proceeding to transplant based on the urgency of the procedure [54, 55]. Low CT values in RT-PCR are associated with the growth of COVID-19 in cultures with high viral loads, so it would be safest to avoid transplanting patients with low CT values [56]. If the candidate is in the second week of illness, then the chances of lesser viral loads are higher [57]. A recent meta-analysis in the general population showed the incidence of RT-PCR positivity as 14.7% between day 41 and day 60 post-discharge [58]. Another meta-analysis showed a 12% incidence of recurrent RT-PCR positivity in post-discharge recovered patients in the general population [59]. The above two studies imply that the fluctuations in RT-PCR between negative and positive after recovery can affect the timing of transplant, so again RT-PCR should not be the sole consideration in a decision about the timing of a transplant (Table 3).

While most reports required normal chest imaging before transplant, owing to high likelihood of residual radiographic changes for months following infection, we suggest the transplant should proceed even in cases of underlying residual damage. There is a report of an ABO kidney transplant where the team waited for inflammatory markers to resolve despite being RT-PCR negative and asymptomatic [60]. However, normalization of inflammatory markers before transplant should not be a mandatory prerequisite. There is an interesting report of four kidney transplantation where the candidates had no symptoms and their RT-PCRs came back positive retrospectively [61]. Interestingly, all recipients did well and remained asymptomatic, except for acute cellular rejection in two cases, which may be attributable to reduction of IS post-operatively out of concern for a possible flare of COVID-19.

Limitations

The limitation of this review is that there are only two cases of heart transplants and one case of SPK in a recovered patient. Hence, our review cannot provide much information about these organs. Future reports with these organs and prospective studies from international registries will throw more light on this topic.

The sensitivity of RT-PCR approximates 70%, so there will be high chances of false-negative reports [62]. A validated better test in the future will be more helpful. At this point, it is prudent to be on the safe side, with repeated RT-PCR assessments in non-emergency transplants. The follow-up in most reports was short, and longer follow-up data in these transplant recipients will provide important information regarding safety and outcomes.

In an additional note, there is a report of a 9-year-old female with short bowel syndrome 3 months of post-COVID-19, which required a small bowel transplant [63]. This indicates that COVID may be part of the transplant world in ways we have not yet anticipated.

Conclusion

In summary, transplantation from SARS-CoV-2 recovered patients has been reported to be safe with good short-term outcomes in multiple case reports and case series, although kidney transplantation is predominant in these reports. The optimal criteria to proceed with transplant should include evidence of a lack of viral replication. Emerging data suggest that a negative RT-PCR report should not be mandatory
Liver transplantation in candidates with recovered or positive SARS-CoV-2 infection. COVID-19 severity was defined as mild in those with only upper respiratory symptoms, moderate when requiring low flow oxygen, and severe in cases with higher oxygen requirement. *=Cases which were RT-PCR positive at the time of transplant surgery. Abbreviations: ALF, acute liver failure; ACLF, acute on chronic liver failure; COVID-19, coronavirus disease; CT, cycle threshold; DD, deceased donation; F, female; HAT, hepatic artery thrombosis; LD, living donation; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus; IS: immunosuppression; M, male; m, months; MMF, mycophenolate; NASH, non-alcoholic steatohepatitis; nRT-PCR, real-time polymerase chain test through nasopharyngeal specimen; PVT, portal venous thrombosis

| Authors                  | n | Type   | Age/sex | Cause of liver disease | COVID-19 severity | Negative nRT-PCR prior to transplant | Waiting time after negative RT-PCR | IgG antibody test Pre-Transplant | Donor’s COVID-19 status | IS regimen | Outcome | Follow-up |
|--------------------------|---|--------|---------|------------------------|-------------------|---------------------------------------|----------------------------------|----------------------------------|----------------------------|------------|---------|-----------|
| Martini et al., July 2020 [71] | 1 | DD     | 39/F    | Autoimmune cirrhosis   | Mild              | 1                                     | 2 d after first negative and 9 d after diagnosis of COVID-19 | Not done                        | Negative                   | No change | Uneventful | 9 d       |
| Tabrizian P et al., Nov 2020 [40] | 1 | DD     | 57/F    | HCV, HIV, HCC          | Mild              | 2                                     | 2 mos                            | Positive                        | Negative                   | No change | Uneventful | 5 mos     |
| Goss MB et al., Nov 2020 [41] | 1 | DD     | 4 yr/M  | Hepatoblastoma         | 4                 | 4                                    | 4 wks. after resolution of symptoms | Positive                        | Negative                   | No change | None     | 10 d      |
| Raut V et al., Feb 2021 [38] | 1 | DD     | 36/M    | Alcoholic cirrhosis    | Moderate          | 4                                     | 6 wks. of recovery                | Not reported                    | Negative                   | No change | None     | 10 d      |
| Rouphael et al., March 2021 [44] | 1 | DD     | 27/F    | Acetaminophen overdose | Mild              | Positive                              | COVID-19 illness started 2 mos. earlier | Not reported                    | Negative                   | No change | None     | 27 d      |
| Durazo FA, March 2021 [48]   | 1 | DD     | 47/M    | Post- COVID-19 cholangiopathy | Severe | Negative                              | Not known                        | Negative                        | No change                   | None       | None     | 7 mos     |
| Gambato et al., April 2021 [45] | 1 | DD     | 63/F    | Ethanol CLD            | Mild              | 1                                     | 45 d from COVID-19; 16 d from -ve report | Negative                        | Negative                   | No change | PVT      | 6 mos     |
| Raj A et al., April 2021 [46] | 1 | LD     | 51/M    | Ethanol CLD            | Mild              | 2 negative                            | 23 d from recovery                | Not reported                    | Negative                   | Lowered dose of maintenance drugs | HAT; 14 and 18 post-op d | Graft loss; Re-transplant at 70 d | Death at 80 d |
| Dhand et al., April 2021 [37] | 1 | DD     | 42/M    | Alcoholic              | Mild              | 1                                     | 71 d from COVID-19; 24 d from negative | Done (negative)                 | Negative                   | No induction/ no MMF | Acute rejection responded | 25 d  |
| Authors             | n | Type   | Age/sex | Cause of liver disease | COVID-19 severity | Negative nRT-PCR prior to transplant | Waiting time after negative RT-PCR | IgG antibody test Pre-Transplant | Donor’s COVID-19 status | IS regimen | Outcome | Follow-up |
|---------------------|---|--------|---------|-------------------------|-------------------|--------------------------------------|----------------------------------|----------------------------------|--------------------------|-------------|---------|-----------|
| Niess et al., April 2021 [47] | 1 | DD     | 56/M    | HBV crypto-genic        | Mild              | 2 (31 d after illness)                | 15 d after negative; and 45 d after illness | Done (positive)                  | Negative                  | Tac level kept low, rest no change | Viral loads retested positive post-transplant | 70 d |
| Natori et al., May 2021 [36••] | 14 | DD:15  | Median:52.3 yr Sex: M:11 F:3 | Not reported | 4 patients had RT-PCR positive at transplant but were IgG positive | Negative PCR not a criterion (4 out of 14 were RT-PCR positive at transplant) | Median: 147 (range 61–202) d | Done in all (4 had IgG positive with PCR positive) | Negative                  | No change   |         | 79 (22–190) d |
| Kulkarni A V et al., June 2021 [35••] | 6 | LD     | Median:35.8 Sex: M:5 F:1 | • ACLF (n = 3) • Alcohol cirrhosis (n = 2) • NASH (n = 1) | Mild (n = 5) Moderate (n = 1) | 2; Last test was done 24 h before transplant | • 4 patients after 2 wks • 2 patients after 4 wks | 1 | Negative | No change | 5 did well • 1 had TCR at POD 42 • 1 died sepsis at POD 24 | ~1 mo |
| Manzia et al., July 2021 * [42] | 1 | DD     | 35/F    | HBV                     | Asymptomatic; X-ray showing ground glass opacities | RT-PCR +ve | Positive RT-PCR | Positive | No change | Uneventful |         | 2 mos |
| Faruqui S. et al., July 2021 [49] | 1 | LD     |         | Post-COVID-19 cholangiopathy | Severe | Negative | No change | Uneventful |         |             |             |             |
| Gonzalez A et al., July 2021 [39] | 1 | DD     | 46/F    | Alcoholic cirrhosis     | Mild     | 2          | 2 wks., 30 d from symptom onset | Not done | Negative | No change | Uneventful | 140 d |
| Yohanathan L et al., Aug 2021 * [43] | 1 | DD     | 18/F    | ALF Wilson’s disease    | Critical; intubated | Positive with low CT values | 17 d from the onset of COVID-19 symptom | Negative | Negative | MMF not started initially | Uneventful | 37 d |
Table 3  Thoracic organ transplantation in candidates with recovered or positive SARS-CoV-2 infection. COVID-19 severity was defined as mild in those with only upper respiratory symptoms, moderate when requiring low flow oxygen, and severe in cases with higher oxygen requirement and critical COVID-19 defined as organ failure. Abbreviations: ARDS, acute respiratory syndrome; COVID-19, coronavirus disease; ECMO, extracorporeal membrane oxygenation; F, female; M, male; m, months; nRT-PCR, real-time polymerase chain test through nasopharyngeal specimen; POD, postoperative
day

| Authors                        | n  | Cause of native organ disease | COVID-19 severity | Waiting time after negative nRT-PCR | IgG antibody test Pre-Transplant | Outcome                           | Follow-up |
|--------------------------------|----|-------------------------------|-------------------|-------------------------------------|---------------------------------|-----------------------------------|-----------|
| Lung transplantation           |    |                               |                   |                                     |                                 |                                   |           |
| Chen JY et al., Jun 2020 [25]  | 3  | • 66/M • 58/M • 73/M         | All had critical COVID-19 | All three on ECMO                  | 42 d                            | • 1 case died POD 1                | POD 22 and 12 for 2 alive patients |
| Han W et al., Jul 2020 [26]    | 2  | • 66/F • 70/M                 | Both had critical COVID-19 | Both on ECMO at the time of transplant | PCR negative; around 2 mos. after first positive report | Uneventful                        | Short follow-up                      |
| Lang C et al., Oct 2020 [27]   | 1  | 44/F                          | Critical COVID-19 | On ECMO at the time of transplant | RT-PCR + ve with high CT value; On 58 d since first positive report | Uneventful                        | 121 d                              |
| Bharat A et al., Dec 2020 [24] | 3  | Median: 44.3 ± 13.9; Sex: M:2 F:1 | All had Critical COVID-19 | All three on ECMO                  | All three had repeated negative RT-PCR | Uneventful                        | 3 to 5 mos                          |
| Croci GA et al., March 2021 [31]| 1  |                               | Mild illness      | 2 mos. back                         | Positive                        |                                   | 6 mos                              |
| Gok et al., April 2021 [72]    | 2  | • 69/M • 63/M                 | • Severe, ARDS on d 0; ARDS on d 6 | • Noninvasive ventilation d 57    | • 41 d                           | • Positive 55 d                    | 30 d                                |
| Bharat A et al., May 2021 [30*] | 12 | Median:48 yr (IQR 41–51); Sex: M:9 F:3 | All had critical COVID-19 | All on ECMO                         | All were on life support         | All patients weaned off ECMO       | Short follow-up                      |
| Oh DK et al., May 2021 [29]    | 1  | 55/F                          | Critical COVID-19; ARDS | On ECMO                             | • 88 d                           | Uneventful                        | 3 mos                                |
| King CS et al., Sept 2021 [28] | 1  | 37/F                          | Critical COVID-19 | On ECMO for 7 wks                   | • 49 d of ECMO                   | Uneventful                        | D 16                                 |
| Heart transplantation          |    |                               |                   |                                     |                                 |                                   |           |
| Soquet et al., Sept 2020 [33]  | 1  | 22/F                          | Giant cell myocarditis; re-transplant | Critical required ECMO            | Within 1 mo | Done (negative throughout hospital course) | Uneventful but persistent RT-PCR + ve | 44 d      |
in all cases to proceed with transplantation. Alteration of early post-transplant immunosuppression in this context does not appear to be necessary, as per the available data. Nevertheless, in cases of life-saving or inadvertent transplantation with active SARS-CoV-2, modifications in the immunosuppressive regimen are justified. There is also a need to gather further information for transplantation of organs such as the lung, pancreas, and intestine, where data are relatively scant. This review of data from available reports through September 2021 may serve as a foundation for decision-making in the challenging approach to transplantation for SARS-CoV-2 recovered patients. Hopefully, the vaccination era will bring a steep decline in these challenging clinical scenarios [64, 65].

Author Contribution All have made equal contributions in the manuscript.

Funding K.L.L. is supported by the Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant R01DK120551.

Data Availability Not applicable.

Code Availability Not applicable.

Compliance with Ethical Standards

Ethics Approval Not required.

Conflict of Interest The authors declare no competing financial interests. K.L.L. is a volunteer member of the American Society of Nephrology (ASN) COVID-19 Response Team.

Informed Consent Not applicable.

References

Papers of particular interest, published recently, have been highlighted as:
● Of importance
●● Of major importance

1. Azzi YBR, Scalea J, Loarte-Campos P, Akalin E. COVID-19 and solid organ transplantation: a review article. Transplantation. 2021;105(1):37–55. https://doi.org/10.1097/TP.0000000000003523. This reference details the overall impact of COVID-19 in solid organ transplantation.

2. Azzi Y, Brooks A, Yaffe H, Greenstein S. COVID-19 and the response of transplant centers: the global response with an emphasis on the kidney recipient. Curr Transplant Rep. 2021;8(3):163–82. https://doi.org/10.1007/s40472-021-00330-5.

Table 3 (continued)

| Authors       | n | Age/sex | Cause of native organ disease | COVID-19 severity | Waiting-time after negative nRT-PCR report | IgG antibody test Pre-Transplant | Outcome | Follow-up | IgG antibody test Post-Transplant | Pre-Transplant | Waiting-time after positive nRT-PCR report | Cause of native organ disease | Waiting-time after positive nRT-PCR report | Cause of native organ disease | Waiting-time after positive nRT-PCR report |
|---------------|---|---------|--------------------------------|-------------------|------------------------------------------|---------------------------------|---------|-----------|-----------------------------------|-----------------|------------------------------------------|---------------------------------|------------------------------------------|-------------------------------|------------------------------------------|
| Johnstad CM et al., March 2021 [32] | 1 63/M Isaac heart disease | Moderate | 15 d of a positive report | Not reported | Uneventful | 17 d | Moderate | 1 mo
| Gaudriot B et al., May 2021 [34] | 1 38/M Post-COVID-19 | Moderate | On ECMO | Not reported | Uneventful | 11 d | Moderate | 1 mo

Table 3 (continued)
3. Boyarsky BJ, Po-Yu Chiang T, Werbel WA, et al. Early impact of COVID-19 on transplant center practices and policies in the United States. Am J Transplant. 2020;20(7):1809–18.

4. Lieberman JA, Mays JA, Wells C, et al. Expedit SARS-CoV-2 screening of donors and recipients supports continued solid organ transplantation. Am J Transplant. 2020;20(11):3106–12.

5. World Health Organization. WHO Dashboard. Available from: https://covid19.who.int/\?gclid=EAIaIQobChMfMnlnK-8Q1V5b0rCh09K0KoSQeEAYASAELEjID_BwE. Last accessed on 6 September 2021.

6. Kute VB, Fleetwood VA, Meshram HS, Guennette A, Lentine KL. Use of organs from SARS-CoV-2 infected donors: is it safe? A contemporary review. Curr Transplant Rep. 2021;8(4):281–92.

7. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study [published correction appears in Lancet. 2020 Jun 9;]. Lancet. 2020;396(10243):27–38. https://doi.org/10.1016/S0140-6736(20)31182-X.

8. Keller BC, Le A, Sobhane M, et al. Early COVID-19 infection after lung transplantation. Am J Transplant. 2020;20(10):2923–7.

9. Kolonko A, Dudzicz S, Wiecek A, Krol R. COVID-19 infection in solid organ transplant recipients: a single-center experience with patients immediately after transplantation. Transplant Infect Dis. 2021;23(1):e13381.

10. Waisberg DR, Abdala E, Naicif LS, et al. Liver transplant recipients infected with SARS-CoV-2 in the early postoperative period: lessons from a single center in the epicenter of the pandemic. Transplant Infect Dis. 2021;23(1):13418.

11. Kucuk EV, Sit D, Kayabasi H, et al. The first kidney transplantation after recipient and living donor recovered from COVID-19. North Clin Istanb. 2021;8(2):187–9.

12. Waghmare I, Singhare A, Bahadur MM, et al. ABO incompatible kidney transplantation after recovery from severe COVID-19 pneumonia. Korean J Transplant. 2020;34 Suppl 1:S56. https://doi.org/10.4285/ATW2020.OP-1179.

13. •Kute VBGS, Guleria S, et al. Is it safe to be transplanted from living donors who recovered from COVID-19? Experience of 31 kidney transplants in a multicenter cohort study from India. Transplantation. 2021;105(4):842–50. https://doi.org/10.1097/TP.0000000000003569. This reference describes the largest cohort of living kidney transplantation in recovered donors which had 9 recovered recipients, till 1 July 2021.

14. ••Kute VBDRD, Yadav DK, et al. A multicenter cohort study from India of 75 kidney transplants in recipients recovered after COVID-19. Transplantation. 2021;105(7):1422–32. https://doi.org/10.1097/TP.0000000000003740. This reference describes the largest cohort of living kidney transplantation in recovered recipients, till July 2021.

15. ••Santeusanio ADBA, Rana M, Lerner S, Shapiro R. Kidney transplantation in patients with prior coronavirus disease 2019 (COVID-19). Clin Transplant. 2021;35(6):e14288. https://doi.org/10.1111/ctr.14288. This reference describes the largest cohort of deceased donor kidney transplantation with prior COVID-19 in candidates.

16. Varotti G, Dodi F, Garibotto G, Fontana I. Successful kidney transplantation after COVID-19. Transpl Int. 2020;33(10):1334–4.

17. Hogan J, Kwon T, Paye-Jaouen A, Fait C, Cointe A, Baudouin V. Kidney transplantation in a COVID-19-positive pediatric recipient. Transplantation. 2021;105(7):e74–5.

18. Murad H, Dubberke E, Mattu M, Parikh B, Wellen J, Alhamad T. Repeat SARS-CoV-2 testing after recovery Is a pretransplant PCR necessary? [published online ahead of print, 2021 Jan 29]. Am J Transplant. 2021. https://doi.org/10.1111/ajt.16506.

19. Puodziukaitė L, Serpytis M, Kundrotaitė A, et al. Kidney transplantation from a SARS-CoV-2-positive donor for the recipients with immunity after COVID-19. Transpl Infect Dis. 2021;23(4):e13666.

20. Singh N, Tandukar S, Zibari G, Naseer MS, Amiri HS, Samaniego-Picota MD. Successful simultaneous pancreas and kidney transplant in a patient post-COVID-19 infection. Kidney Int. 2020;98(6):1615–6.

21. Alcázar-Arroyo R, Portolés J, López-Sánchez P, et al. Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study. Clin Kidney J. 2021;14(7):1835–44. https://doi.org/10.1093/ckj/sfab048.

22. Ramanathan K, Shekar K, Ling RR, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Crit Care. 2021;25(1):211.

23. Schmidt M, Hajage D, Lebretón G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study. Lancet Respir Med. 2020;8(11):1121–31.

24. Bharat A, Querrey M, Markov NS, et al. Lung transplantation for patients with severe COVID-19. Sci Transl Med. 2020;12(574):eaba4282. https://doi.org/10.1126/scitranslmed.abe4282.

25. Chen JY, Qiao K, Liu F, et al. Lung transplantation as a therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis. Chin Med J (Engl). 2020;133(12):1390–6. https://doi.org/10.1097/CM9.0000000000000839.

26. Han W, Zhu M, Chen J, et al. Lung transplantation for elderly patients with end-stage COVID-19 pneumonia. Ann Surg. 2020;272(1):e33–4.

27. Lang C, Jaksch P, Hoda MA, et al. Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient. Lancet Respir Med. 2020;8(10):1057–60.

28. King CS, Mannem H, Kukreja A, Aryal S, Tang D, Singer JP, Bharat A, Behr J, Nathan SD. How I do it: considering lung transplantation for patients with COVID-19. Chest. 2021. https://doi.org/10.1016/j.chest.2021.08.041.

29. Oh DK, Hong SB, Kim HC, et al. Experience of international air transportation and subsequent lung transplant in a patient with COVID-19-associated acute respiratory distress syndrome: a case report. J Korean Med Sci. 2021;36(17):e123.

30. ••Bharat AMT, Querrey M, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med. 2021;9(5):487–97. https://doi.org/10.1016/S2213-2600(21)00077-1. This reference describes the largest case series of lung transplantation in COVID-19 till 1 July 2021.

31. Croci GA, Vaira V, Trabattoni D, et al. Emergency lung transplantation after COVID-19: immunopathological insights on two affected patients. Cells. 2021;10(3):611. https://doi.org/10.3390/cells10030611.

32. Johnstad CM, Murray D, Dhingra R, Smith JW, Fiedler AG. Successful heart transplantation in a patient who recovered from COVID-19. J Card Surg. 2021;36(3):1148–9.

33. Soquet J, Rouse N, Moussa M, et al. Heart retransplantation following COVID-19 illness in a heart transplant recipient. J Heart Lung Transplant. 2020;39(9):983–5.

34. Gaudriot B, Mansour A, Thibault V, et al. Successful heart transplantation for COVID-19-associated post-infectious fulminant myocarditis. ESC Heart Fail. 2021;8(4):2625–30.

35. ••Kulkarni AVPK, Kumar P, et al. Early liver transplantation after COVID-19 infection: the first report. Am J Transplant. 2021;21(6):2279–84. https://doi.org/10.1111/ajt.16509.
reference describes the largest cohort of living liver transplant of COVID-19 recovered candidates.

36. ●Natori Y AS, Martin EF, et al. When is it safe to perform abdominal transplantation in patients with prior SARS-CoV-2 infection: a case series [published online ahead of print, 2021 May 25]. Clin Transplant. 2021;e14370. https://doi.org/10.1111/ctr.14370. This reference describes the largest cohort of deceased donor liver transplant of COVID-19 recovered candidates.

37. Dhand A, Bodin R, Wolf DC, et al. Successful liver transplantation in a patient recovered from COVID-19. Transpl Infect Dis. 2021;23(2):e13492.

38. Raut V, Sonavane A, Shah K, et al. Successful liver transplantation immediately after recovery from COVID-19 in a highly endemic area. Transpl Int. 2021;34(2):376–7.

39. Gonzalez A, Zervos X, Pinna A, et al. Orthotopic liver transplantation in a cirrhotic patient with recent COVID-19 infection. ACG Case Rep J. 2021;8(7):e00634.

40. Tabrizian P, Pourmand K, Florman S. Liver transplantation in a patient with human immunodeficiency virus and coronavirus disease 2019 [published online ahead of print, 2020 Nov 18]. Liver Transpl. 2020. https://doi.org/10.1002/lt.25947.

41. Goss MB, Munoz FM, Ruan W, et al. Liver transplant in a recently COVID-19 positive child with hepatoblastoma. Pediatr Transplant. 2021;25(5):e13880. https://doi.org/10.1111/petr.13880.

42. Manzia TM, Gazia C, Lenci I, et al. Liver transplantation performed in a SARS-CoV-2 positive hospitalized recipient using a SARS-CoV-2 infected donor [published online ahead of print, 2021 Feb 23]. Am J Transplant. 2021. https://doi.org/10.1111/ajt.16548.

43. Yohanathan L, Campioli CC, Mousa OY, et al. Liver transplantation for acute liver failure in a SARS-CoV-2 PCR-positive patient [published online ahead of print, 2021 Mar 31]. Am J Transplant. 2021. https://doi.org/10.1111/ajt.16582.

44. Rouphael C, D’Amico G, Ricci K, et al. Successful orthotopic liver transplantation in a patient with a positive SARS-CoV2 test and acute liver failure secondary to acetaminophen overdose. Am J Transplant. 2021;21(3):1312–6.

45. Gambato M, Germani G, Perini B, et al. A challenging liver transplantation for decompensated alcoholic liver disease after recovery from SARS-CoV-2 infection. Transpl Int. 2021;34(4):756–7.

46. Raj A, Shankar V, Singhal S, et al. Recurrent hepatic artery thrombosis following living donor liver transplant as sequelae of SARS-CoV-2 infection: case report, 20 May 2021, PREPRINT (Version 1) available at Research Square. Under review.https://doi.org/10.21203/rs.3.rs-497240/v1.

47. Niess H, Börner N, Muenchhoff M, et al. Liver transplantation in a patient after COVID-19 - rapid loss of antibodies and prolonged viral RNA shedding. Am J Transplant. 2021;21(4):1629–32.

48. Durazo FA, Nicholas AA, Mahaffey JJ, et al. Post-Covid-19 cholangiopathy-a new indication for liver transplantation: a case report. Transplant Proc. 2021;53(4):1132–7.

49. Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy after severe COVID-19: clinical features and prognostic implications. Am J Gastroenterol. 2021;116(7):1414–25.

50. ASA and APSF Joint Statement on Elective Surgery and Anesthesia for Patients after COVID-19 Infection. 8 Dec 2020. Available from: https://www.asahq.org/about-asa/newsroom/news-releases/2020/12/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-for-patients-after-covid-19-infection. Last accessed on 1 July 2021.

51. The International Society of Heart and Lung Transplantation: Guidance from the International Society of Heart and Lung Transplantation regarding the SARS-CoV-2 pandemic. Revised February 1 2021. https://ashh.org/shef/media/documents/SARS-CoV-2:_Guidance-for-Cardiothoracic-Transplant-and-VAD-centers.pdf. Last accessed on 28 June 2021.

52. Kute VB, Guleria S, Bhalla AK, Sharma A, Agarwal SK, Sahay M, et al. ISOT consensus statement for the kidney transplant recipient and living donor with a previous diagnosis of COVID 19. Indian J Transplant. 2021;15:131–3.

53. Di Maira T, Berenguer M. COVID-19 and liver transplantation. Nat Rev Gastroenterol Hepatol. 2020;17(9):526–8.

54. Rao SN, Manissero D, Steele VR, Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19 [published correction appears in Infect Dis Ther. 2020 Aug 18;:]. Infect Dis Ther. 2020;9(3):573–86. https://doi.org/10.1007/s40121-020-00324-3.

55. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020;71(10):2663–6.

56. Gniadkowski V, Morris CP, Wohl S, et al. Repeat COVID-19 molecular testing: correlation of SARS-CoV-2 culture with molecular assays and cycle thresholds [published online ahead of print, 2020 Oct 27]. Clin Infect Dis. 2020;cia1616. doi: https://doi.org/10.1093/cid/cia1616.

57. To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–74.

58. Cento V, Colagrossi L, Nava A, et al. Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. J Infect. 2020;81(3):e90–2.

59. Mattiuzzi C, Henry BM, Sanchis-Gomar F, Lippi G. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta Biomed. 2020;91(3):e2020014.

60. Waghmare I, Shingare A, Bahadur M. ABO incompatible kidney transplant after recovery from severe COVID-19 pneumonia. Korean J Transplant. 2020;34:S56. https://doi.org/10.4285/ATW2020.OP-1179.

61. Viana LA, Cristelli MP, Fischer KN, et al. Kidney transplantation in patients with SARS-CoV-2 infection: a case series report. Transplantation. 2021;105(1):e1–3.

62. Kang H, Wang Y, Tong Z, Liu X. Retest positive for SARS-CoV-2 RNA of “recovered” patients with COVID-19: persistence, sampling issues, or re-infection? J Med Virol. 2020;92(11):2263–5.

63. Chaubal G, Hatimi H, Nanavati A, Deshpande A, Andankar P, Birader V, Gupte P, Hanchane P. Pediatric living donor intestine transplant following an atypical complication of COVID-19: a unique case report from India. Am J Transplant. Accepted Author Manuscript. 2021. https://doi.org/10.1111/ajt.16798.

64. Lentine KL, Mannon RB, Josephson MA. Practicing With Uncertainty: Kidney Transplantation During the COVID-19 Pandemic. Am J Kidney Dis. 2021;77(5):777–85. https://doi.org/10.1053/j.ajkd.2020.12.003.

65. Hippen BE, Axelrod DA, Maher K, et al. Survey of current transplant center practices regarding COVID-19 vaccine mandates in the United States. Am J Transplant. 2022. https://doi.org/10.1111/ajt.16995 [epub ahead of print].

66. Kanchi P, Sambhandam S, Siddhan R, Soundaparan S, Vaseekaran VP, Gupta A. Successful kidney transplantation after COVID-19 infection in two cases [published online ahead of print, 2021 Jan 9]. Nefrologia (Engl Ed). 2021;S0211–6995(21):00002–3. https://doi.org/10.1016/j.nefro.2020.12.004.

67. Yoshinaga K, Araki M, Wada K, et al. Successful deceased donor kidney transplantation to a recipient with a history of COVID-19 treatment. J Infect Chemother. 2021;27(7):1097–101.
Reyad AI, Dao A, Guiteau JJ, Madhira MM, Allam SR. Successful Kidney transplantation after recovery from COVID-19. J Clin Exp Transplant. 2021;6:132. https://doi.org/10.4172/2475-7640.1000132.

Villanego F, Vigara LA, Torrado J, et al. SARS-CoV-2 infection on the kidney transplant waiting list: can a patient be transplanted after COVID-19? [published online ahead of print, 2021 Jan 9]. Infección por SARS-CoV-2 en lista de espera de trasplante renal: ¿se puede trasplantar un paciente con antecedente de COVID-19? [published online ahead of print, 2021 Jan 9]. Nefrologia (Engl Ed). 2021;S0211–6995(21)00001–1. https://doi.org/10.1016/j.nefro.2020.12.003.

Tuschen K, Anders J, Elfanih A, et al. Renal transplantation after recovery from COVID-19 - a case report with implications for transplant programs in the face of the ongoing corona-pandemic. BMC Nephrol. 2021;22(1):251. https://doi.org/10.1186/s12882-021-02448-1.

Martini S, Patrono D, Pittaluga F, et al. Urgent liver transplantation soon after recovery from COVID-19 in a patient with decompensated liver cirrhosis. Hepatol Commun. 2020.

Gok E, Patel M, Stojkovic BP, et al. Lung transplantation in COVID-19 ARDS - short term outcomes. J Heart Lung Transplant. 2021;40(4, Supplement):S500–1.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.